The human antibody repertoire, or reactome, is a vast and dynamic network of antibody-antigen interactions that plays a crucial role in health and disease. Understanding the complexity of this network [….]
QIAGEN Expands QIAstat-Dx into Precision Medicine Through Partnership for Companion Diagnostics in Chronic Diseases This new agreement expands collaboration with AstraZeneca beyond oncology, including complex chronic diseases. QIAGEN’s syndromic testing [….]
TEDCO Fuels Biotech Innovation in Maryland: Key Investments in Two FITCI Client Companies TEDCO strengthens Maryland’s biotech ecosystem with strategic investments in NEOPATHOLOGY CORP. and Simmbion, LLC, both innovative companies [….]
Galaxy Diagnostics Launching More Tests for Deadly Infections Nicole Bell has taken the helm of Morrisville-based Galaxy Diagnostics, leading the company to launch groundbreaking tests for Lyme disease and Bartonella, [….]
Spotlight Your Start-up: Apply to Compete in the 9th Annual Crab Trap Competition July 17, 2024 Get ready to showcase your start-up at the BioHealth Capital Region Week! The 9th [….]
Maxim Biomedical, Inc. Secures Second NIH RADx Tech High Performance Award for Continued Development of At-Home FiarFly™ Reader and COVID-19 & Flu A/B Rapid Test NEWS PROVIDED BYMaxim Biomedical, Inc. [….]
New Company Launches to Offer Development of Point-of-Care Rapid Immunodiagnostic Lateral Flow Tests San Diego, CA – August 24, 2023 – Gold Colloid, Co., a new company focused on the [….]
Delfi Diagnostics, a Baltimore-based company developing liquid biopsy tests for early cancer detection, will highlight its next-generation liquid biopsy platform at the American Association for Cancer Research’s (AACR) 2023 annual meeting in April.
Capital Digestive Care is delighted to announce that our new, 22,000 square foot, state-of-the-art laboratory has been recognized as a Roche Diagnostics Center of Excellence, the first GI specialty practice in the United States with the designation.
Diagnostic startup Senzo is developing an at-home COVID-19 test that’s as reliable as a PCR
Following a promising early study, the company hopes to take the product to market before the end of the year and add some Philly-based team members. By Paige Gross / STAFF
Join 30,000+ readers who receive daily email updates from Technical.ly
ADVERTISEMENT
About SEER Interactive FIND OUT MORE
TOP ARTICLES
1
How to operationalize your company values
2
RealLIST Connectors: These are the 100 influential leaders to know in Pittsburgh tech
3
RealLIST Connectors 2022: Get to know 22 leaders making Philly’s tech and biz ecosystem stronger
Senzo’s Amplified Lateral Flow COVID-19 test.
(Courtesy photo)
If you’ve headed to a work event, family gathering or crowded space in the last two years, it’s likely you’ve taken an at-home COVID-19 test to check your viral status.
It’s how much of the world is responsibly operating in the “new normal” right now, as we manage the ongoing pandemic while returning to something like pre-2020 life. And one Philly-area startup is hoping its tests can be a part of that system.
Senzo, a point-of-care and self-testing diagnostics company, announced this week it received 100% accuracy ratings of its Amplified…
